nodes	percent_of_prediction	percent_of_DWPC	metapath
Delavirdine—CYP2C8—Tazarotene—psoriasis	0.0551	0.079	CbGbCtD
Delavirdine—CYP3A5—Beclomethasone—psoriasis	0.0533	0.0764	CbGbCtD
Delavirdine—CYP1A2—Clobetasol propionate—psoriasis	0.0524	0.075	CbGbCtD
Delavirdine—CYP1A2—Methoxsalen—psoriasis	0.0275	0.0394	CbGbCtD
Delavirdine—CYP2D6—Hydroxyurea—psoriasis	0.0248	0.0355	CbGbCtD
Delavirdine—CYP2C8—Cholecalciferol—psoriasis	0.0235	0.0337	CbGbCtD
Delavirdine—CYP3A7—Hydrocortisone—psoriasis	0.0227	0.0325	CbGbCtD
Delavirdine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0227	0.0325	CbGbCtD
Delavirdine—CYP3A7—Cyclosporine—psoriasis	0.0214	0.0307	CbGbCtD
Delavirdine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0214	0.0307	CbGbCtD
Delavirdine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0212	0.0304	CbGbCtD
Delavirdine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0204	0.0292	CbGbCtD
Delavirdine—CYP2C19—Cholecalciferol—psoriasis	0.0197	0.0283	CbGbCtD
Delavirdine—CYP3A4—Calcitriol—psoriasis	0.0185	0.0265	CbGbCtD
Delavirdine—CYP3A5—Hydrocortisone—psoriasis	0.017	0.0244	CbGbCtD
Delavirdine—CYP2C9—Cholecalciferol—psoriasis	0.0164	0.0235	CbGbCtD
Delavirdine—CYP2C8—Hydrocortisone—psoriasis	0.0164	0.0235	CbGbCtD
Delavirdine—CYP3A5—Cyclosporine—psoriasis	0.0161	0.023	CbGbCtD
Delavirdine—CYP2C8—Cyclosporine—psoriasis	0.0155	0.0222	CbGbCtD
Delavirdine—CYP2D6—Cholecalciferol—psoriasis	0.015	0.0215	CbGbCtD
Delavirdine—CYP3A4—Methoxsalen—psoriasis	0.0144	0.0206	CbGbCtD
Delavirdine—CYP3A7—Dexamethasone—psoriasis	0.0141	0.0202	CbGbCtD
Delavirdine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0141	0.0202	CbGbCtD
Delavirdine—CYP2C19—Prednisone—psoriasis	0.0137	0.0196	CbGbCtD
Delavirdine—CYP2C19—Cyclosporine—psoriasis	0.013	0.0186	CbGbCtD
Delavirdine—CYP2C9—Cyclosporine—psoriasis	0.0108	0.0154	CbGbCtD
Delavirdine—CYP3A5—Dexamethasone—psoriasis	0.0106	0.0152	CbGbCtD
Delavirdine—CYP2C8—Dexamethasone—psoriasis	0.0102	0.0146	CbGbCtD
Delavirdine—CYP2D6—Cyclosporine—psoriasis	0.00986	0.0141	CbGbCtD
Delavirdine—CYP3A4—Cholecalciferol—psoriasis	0.00955	0.0137	CbGbCtD
Delavirdine—CYP2C19—Dexamethasone—psoriasis	0.00854	0.0122	CbGbCtD
Delavirdine—CYP3A4—Triamcinolone—psoriasis	0.00828	0.0119	CbGbCtD
Delavirdine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00828	0.0119	CbGbCtD
Delavirdine—CYP2C9—Dexamethasone—psoriasis	0.0071	0.0102	CbGbCtD
Delavirdine—CYP3A4—Betamethasone—psoriasis	0.0071	0.0102	CbGbCtD
Delavirdine—CYP3A4—Prednisolone—psoriasis	0.00701	0.01	CbGbCtD
Delavirdine—CYP3A4—Hydrocortisone—psoriasis	0.00664	0.00951	CbGbCtD
Delavirdine—CYP3A4—Prednisone—psoriasis	0.00662	0.00948	CbGbCtD
Delavirdine—CYP2D6—Dexamethasone—psoriasis	0.0065	0.0093	CbGbCtD
Delavirdine—CYP3A4—Cyclosporine—psoriasis	0.00627	0.00898	CbGbCtD
Delavirdine—CYP3A4—Dexamethasone—psoriasis	0.00413	0.00592	CbGbCtD
Delavirdine—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00124	0.0552	CbGpPWpGaD
Delavirdine—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00123	0.0547	CbGpPWpGaD
Delavirdine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00111	0.0493	CbGpPWpGaD
Delavirdine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00102	0.0453	CbGpPWpGaD
Delavirdine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00101	0.045	CbGpPWpGaD
Delavirdine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00095	0.0423	CbGpPWpGaD
Delavirdine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000888	0.0395	CbGpPWpGaD
Delavirdine—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000769	0.0342	CbGpPWpGaD
Delavirdine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000686	0.0306	CbGpPWpGaD
Delavirdine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000631	0.0281	CbGpPWpGaD
Delavirdine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000626	0.0279	CbGpPWpGaD
Delavirdine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000535	0.0238	CbGpPWpGaD
Delavirdine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00051	0.0227	CbGpPWpGaD
Delavirdine—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000503	0.0224	CbGpPWpGaD
Delavirdine—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000413	0.0184	CbGpPWpGaD
Delavirdine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000413	0.0184	CbGpPWpGaD
Delavirdine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000369	0.0164	CbGpPWpGaD
Delavirdine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000364	0.0162	CbGpPWpGaD
Delavirdine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000319	0.0142	CbGpPWpGaD
Delavirdine—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000315	0.014	CbGpPWpGaD
Delavirdine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000299	0.0133	CbGpPWpGaD
Delavirdine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000285	0.0127	CbGpPWpGaD
Delavirdine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000281	0.0125	CbGpPWpGaD
Delavirdine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000262	0.0117	CbGpPWpGaD
Delavirdine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00026	0.0116	CbGpPWpGaD
Delavirdine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000259	0.0115	CbGpPWpGaD
Delavirdine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000259	0.0115	CbGpPWpGaD
Delavirdine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000256	0.0114	CbGpPWpGaD
Delavirdine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000231	0.0103	CbGpPWpGaD
Delavirdine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000222	0.00989	CbGpPWpGaD
Delavirdine—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.00022	0.00978	CbGpPWpGaD
Delavirdine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000219	0.00976	CbGpPWpGaD
Delavirdine—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000217	0.00964	CbGpPWpGaD
Delavirdine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000213	0.00946	CbGpPWpGaD
Delavirdine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000211	0.00938	CbGpPWpGaD
Delavirdine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00018	0.00802	CbGpPWpGaD
Delavirdine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000171	0.00763	CbGpPWpGaD
Delavirdine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000169	0.00753	CbGpPWpGaD
Delavirdine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000159	0.00707	CbGpPWpGaD
Delavirdine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000157	0.00697	CbGpPWpGaD
Delavirdine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000139	0.00619	CbGpPWpGaD
Delavirdine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00612	CbGpPWpGaD
Delavirdine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000137	0.0061	CbGpPWpGaD
Delavirdine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00604	CbGpPWpGaD
Delavirdine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000123	0.00546	CbGpPWpGaD
Delavirdine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000121	0.00539	CbGpPWpGaD
Delavirdine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000119	0.00531	CbGpPWpGaD
Delavirdine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000119	0.0053	CbGpPWpGaD
Delavirdine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000113	0.00503	CbGpPWpGaD
Delavirdine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000112	0.00498	CbGpPWpGaD
Delavirdine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000111	0.00496	CbGpPWpGaD
Delavirdine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.00011	0.00491	CbGpPWpGaD
Delavirdine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000109	0.00487	CbGpPWpGaD
Delavirdine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000109	0.00485	CbGpPWpGaD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000107	0.00474	CbGpPWpGaD
Delavirdine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000102	0.00454	CbGpPWpGaD
Delavirdine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	9.56e-05	0.00426	CbGpPWpGaD
Delavirdine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	9.43e-05	0.0042	CbGpPWpGaD
Delavirdine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	9.42e-05	0.00419	CbGpPWpGaD
Delavirdine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	9.27e-05	0.00413	CbGpPWpGaD
Delavirdine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.32e-05	0.0037	CbGpPWpGaD
Delavirdine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	8.25e-05	0.00367	CbGpPWpGaD
Delavirdine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.87e-05	0.0035	CbGpPWpGaD
Delavirdine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.38e-05	0.00329	CbGpPWpGaD
Delavirdine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.28e-05	0.00324	CbGpPWpGaD
Delavirdine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.11e-05	0.00317	CbGpPWpGaD
Delavirdine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7.08e-05	0.00315	CbGpPWpGaD
Delavirdine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.51e-05	0.0029	CbGpPWpGaD
Delavirdine—Malnutrition—Prednisone—psoriasis	6.39e-05	0.000229	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	6.39e-05	0.000229	CcSEcCtD
Delavirdine—Hyperhidrosis—Triamcinolone—psoriasis	6.38e-05	0.000228	CcSEcCtD
Delavirdine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.37e-05	0.00283	CbGpPWpGaD
Delavirdine—Feeling abnormal—Mycophenolate mofetil—psoriasis	6.34e-05	0.000227	CcSEcCtD
Delavirdine—Insomnia—Hydrocortisone—psoriasis	6.34e-05	0.000227	CcSEcCtD
Delavirdine—Hypertension—Betamethasone—psoriasis	6.33e-05	0.000227	CcSEcCtD
Delavirdine—Hypertension—Dexamethasone—psoriasis	6.33e-05	0.000227	CcSEcCtD
Delavirdine—Paraesthesia—Hydrocortisone—psoriasis	6.29e-05	0.000225	CcSEcCtD
Delavirdine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.29e-05	0.000225	CcSEcCtD
Delavirdine—Urticaria—Cyclosporine—psoriasis	6.27e-05	0.000224	CcSEcCtD
Delavirdine—Myalgia—Dexamethasone—psoriasis	6.25e-05	0.000224	CcSEcCtD
Delavirdine—Myalgia—Betamethasone—psoriasis	6.25e-05	0.000224	CcSEcCtD
Delavirdine—Body temperature increased—Cyclosporine—psoriasis	6.23e-05	0.000223	CcSEcCtD
Delavirdine—Abdominal pain—Cyclosporine—psoriasis	6.23e-05	0.000223	CcSEcCtD
Delavirdine—Anxiety—Betamethasone—psoriasis	6.23e-05	0.000223	CcSEcCtD
Delavirdine—Anxiety—Dexamethasone—psoriasis	6.23e-05	0.000223	CcSEcCtD
Delavirdine—Vomiting—Mycophenolic acid—psoriasis	6.2e-05	0.000222	CcSEcCtD
Delavirdine—Discomfort—Dexamethasone—psoriasis	6.17e-05	0.000221	CcSEcCtD
Delavirdine—Discomfort—Betamethasone—psoriasis	6.17e-05	0.000221	CcSEcCtD
Delavirdine—Dyspepsia—Hydrocortisone—psoriasis	6.17e-05	0.000221	CcSEcCtD
Delavirdine—Rash—Mycophenolic acid—psoriasis	6.15e-05	0.00022	CcSEcCtD
Delavirdine—Dermatitis—Mycophenolic acid—psoriasis	6.14e-05	0.00022	CcSEcCtD
Delavirdine—Pain—Prednisolone—psoriasis	6.14e-05	0.00022	CcSEcCtD
Delavirdine—Hepatitis—Methotrexate—psoriasis	6.13e-05	0.00022	CcSEcCtD
Delavirdine—Urticaria—Mycophenolate mofetil—psoriasis	6.11e-05	0.000219	CcSEcCtD
Delavirdine—Headache—Mycophenolic acid—psoriasis	6.11e-05	0.000219	CcSEcCtD
Delavirdine—Decreased appetite—Hydrocortisone—psoriasis	6.09e-05	0.000218	CcSEcCtD
Delavirdine—Pharyngitis—Methotrexate—psoriasis	6.09e-05	0.000218	CcSEcCtD
Delavirdine—Body temperature increased—Mycophenolate mofetil—psoriasis	6.08e-05	0.000218	CcSEcCtD
Delavirdine—Abdominal pain—Mycophenolate mofetil—psoriasis	6.08e-05	0.000218	CcSEcCtD
Delavirdine—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.05e-05	0.000217	CcSEcCtD
Delavirdine—Fatigue—Hydrocortisone—psoriasis	6.04e-05	0.000216	CcSEcCtD
Delavirdine—Vision blurred—Prednisone—psoriasis	6.02e-05	0.000216	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.01e-05	0.000215	CcSEcCtD
Delavirdine—Pain—Hydrocortisone—psoriasis	5.99e-05	0.000215	CcSEcCtD
Delavirdine—Oedema—Betamethasone—psoriasis	5.99e-05	0.000214	CcSEcCtD
Delavirdine—Oedema—Dexamethasone—psoriasis	5.99e-05	0.000214	CcSEcCtD
Delavirdine—Insomnia—Triamcinolone—psoriasis	5.97e-05	0.000214	CcSEcCtD
Delavirdine—Infection—Dexamethasone—psoriasis	5.95e-05	0.000213	CcSEcCtD
Delavirdine—Infection—Betamethasone—psoriasis	5.95e-05	0.000213	CcSEcCtD
Delavirdine—Ill-defined disorder—Prednisone—psoriasis	5.93e-05	0.000212	CcSEcCtD
Delavirdine—Paraesthesia—Triamcinolone—psoriasis	5.93e-05	0.000212	CcSEcCtD
Delavirdine—Feeling abnormal—Prednisolone—psoriasis	5.91e-05	0.000212	CcSEcCtD
Delavirdine—Anaemia—Prednisone—psoriasis	5.91e-05	0.000211	CcSEcCtD
Delavirdine—Shock—Dexamethasone—psoriasis	5.89e-05	0.000211	CcSEcCtD
Delavirdine—Shock—Betamethasone—psoriasis	5.89e-05	0.000211	CcSEcCtD
Delavirdine—Dyspnoea—Triamcinolone—psoriasis	5.88e-05	0.000211	CcSEcCtD
Delavirdine—Agitation—Prednisone—psoriasis	5.87e-05	0.00021	CcSEcCtD
Delavirdine—Thrombocytopenia—Betamethasone—psoriasis	5.86e-05	0.00021	CcSEcCtD
Delavirdine—Thrombocytopenia—Dexamethasone—psoriasis	5.86e-05	0.00021	CcSEcCtD
Delavirdine—Tachycardia—Betamethasone—psoriasis	5.84e-05	0.000209	CcSEcCtD
Delavirdine—Tachycardia—Dexamethasone—psoriasis	5.84e-05	0.000209	CcSEcCtD
Delavirdine—Angioedema—Prednisone—psoriasis	5.84e-05	0.000209	CcSEcCtD
Delavirdine—Hypersensitivity—Cyclosporine—psoriasis	5.81e-05	0.000208	CcSEcCtD
Delavirdine—Dyspepsia—Triamcinolone—psoriasis	5.81e-05	0.000208	CcSEcCtD
Delavirdine—Erythema multiforme—Methotrexate—psoriasis	5.8e-05	0.000208	CcSEcCtD
Delavirdine—Nausea—Mycophenolic acid—psoriasis	5.79e-05	0.000207	CcSEcCtD
Delavirdine—Hyperhidrosis—Dexamethasone—psoriasis	5.79e-05	0.000207	CcSEcCtD
Delavirdine—Hyperhidrosis—Betamethasone—psoriasis	5.79e-05	0.000207	CcSEcCtD
Delavirdine—Feeling abnormal—Hydrocortisone—psoriasis	5.78e-05	0.000207	CcSEcCtD
Delavirdine—Malaise—Prednisone—psoriasis	5.76e-05	0.000206	CcSEcCtD
Delavirdine—Vertigo—Prednisone—psoriasis	5.74e-05	0.000206	CcSEcCtD
Delavirdine—Gastrointestinal pain—Hydrocortisone—psoriasis	5.73e-05	0.000205	CcSEcCtD
Delavirdine—Syncope—Prednisone—psoriasis	5.73e-05	0.000205	CcSEcCtD
Delavirdine—Tinnitus—Methotrexate—psoriasis	5.72e-05	0.000205	CcSEcCtD
Delavirdine—Anorexia—Dexamethasone—psoriasis	5.71e-05	0.000204	CcSEcCtD
Delavirdine—Anorexia—Betamethasone—psoriasis	5.71e-05	0.000204	CcSEcCtD
Delavirdine—Urticaria—Prednisolone—psoriasis	5.7e-05	0.000204	CcSEcCtD
Delavirdine—Fatigue—Triamcinolone—psoriasis	5.69e-05	0.000204	CcSEcCtD
Delavirdine—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.67e-05	0.000203	CcSEcCtD
Delavirdine—Asthenia—Cyclosporine—psoriasis	5.66e-05	0.000203	CcSEcCtD
Delavirdine—Pain—Triamcinolone—psoriasis	5.64e-05	0.000202	CcSEcCtD
Delavirdine—Loss of consciousness—Prednisone—psoriasis	5.62e-05	0.000201	CcSEcCtD
Delavirdine—Hypotension—Betamethasone—psoriasis	5.6e-05	0.0002	CcSEcCtD
Delavirdine—Hypotension—Dexamethasone—psoriasis	5.6e-05	0.0002	CcSEcCtD
Delavirdine—Pruritus—Cyclosporine—psoriasis	5.58e-05	0.0002	CcSEcCtD
Delavirdine—Urticaria—Hydrocortisone—psoriasis	5.57e-05	0.000199	CcSEcCtD
Delavirdine—Body temperature increased—Hydrocortisone—psoriasis	5.54e-05	0.000198	CcSEcCtD
Delavirdine—Abdominal pain—Hydrocortisone—psoriasis	5.54e-05	0.000198	CcSEcCtD
Delavirdine—Asthenia—Mycophenolate mofetil—psoriasis	5.52e-05	0.000198	CcSEcCtD
Delavirdine—Hypertension—Prednisone—psoriasis	5.52e-05	0.000197	CcSEcCtD
Delavirdine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.51e-05	0.00245	CbGpPWpGaD
Delavirdine—Chills—Methotrexate—psoriasis	5.5e-05	0.000197	CcSEcCtD
Delavirdine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.49e-05	0.00244	CbGpPWpGaD
Delavirdine—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.46e-05	0.000195	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Betamethasone—psoriasis	5.46e-05	0.000195	CcSEcCtD
Delavirdine—Pruritus—Mycophenolate mofetil—psoriasis	5.44e-05	0.000195	CcSEcCtD
Delavirdine—Myalgia—Prednisone—psoriasis	5.44e-05	0.000195	CcSEcCtD
Delavirdine—Arthralgia—Prednisone—psoriasis	5.44e-05	0.000195	CcSEcCtD
Delavirdine—Feeling abnormal—Triamcinolone—psoriasis	5.44e-05	0.000195	CcSEcCtD
Delavirdine—Anxiety—Prednisone—psoriasis	5.42e-05	0.000194	CcSEcCtD
Delavirdine—Alopecia—Methotrexate—psoriasis	5.42e-05	0.000194	CcSEcCtD
Delavirdine—Insomnia—Betamethasone—psoriasis	5.42e-05	0.000194	CcSEcCtD
Delavirdine—Insomnia—Dexamethasone—psoriasis	5.42e-05	0.000194	CcSEcCtD
Delavirdine—Diarrhoea—Cyclosporine—psoriasis	5.4e-05	0.000193	CcSEcCtD
Delavirdine—Paraesthesia—Dexamethasone—psoriasis	5.38e-05	0.000192	CcSEcCtD
Delavirdine—Paraesthesia—Betamethasone—psoriasis	5.38e-05	0.000192	CcSEcCtD
Delavirdine—Discomfort—Prednisone—psoriasis	5.37e-05	0.000192	CcSEcCtD
Delavirdine—Malnutrition—Methotrexate—psoriasis	5.34e-05	0.000191	CcSEcCtD
Delavirdine—Erythema—Methotrexate—psoriasis	5.34e-05	0.000191	CcSEcCtD
Delavirdine—Hypersensitivity—Prednisolone—psoriasis	5.29e-05	0.000189	CcSEcCtD
Delavirdine—Dyspepsia—Dexamethasone—psoriasis	5.27e-05	0.000189	CcSEcCtD
Delavirdine—Dyspepsia—Betamethasone—psoriasis	5.27e-05	0.000189	CcSEcCtD
Delavirdine—Diarrhoea—Mycophenolate mofetil—psoriasis	5.26e-05	0.000188	CcSEcCtD
Delavirdine—Urticaria—Triamcinolone—psoriasis	5.24e-05	0.000188	CcSEcCtD
Delavirdine—Dysgeusia—Methotrexate—psoriasis	5.23e-05	0.000187	CcSEcCtD
Delavirdine—Body temperature increased—Triamcinolone—psoriasis	5.22e-05	0.000187	CcSEcCtD
Delavirdine—Dizziness—Cyclosporine—psoriasis	5.22e-05	0.000187	CcSEcCtD
Delavirdine—Oedema—Prednisone—psoriasis	5.21e-05	0.000187	CcSEcCtD
Delavirdine—Decreased appetite—Dexamethasone—psoriasis	5.21e-05	0.000186	CcSEcCtD
Delavirdine—Decreased appetite—Betamethasone—psoriasis	5.21e-05	0.000186	CcSEcCtD
Delavirdine—Infection—Prednisone—psoriasis	5.18e-05	0.000185	CcSEcCtD
Delavirdine—Gastrointestinal disorder—Dexamethasone—psoriasis	5.17e-05	0.000185	CcSEcCtD
Delavirdine—Gastrointestinal disorder—Betamethasone—psoriasis	5.17e-05	0.000185	CcSEcCtD
Delavirdine—Back pain—Methotrexate—psoriasis	5.17e-05	0.000185	CcSEcCtD
Delavirdine—Hypersensitivity—Hydrocortisone—psoriasis	5.16e-05	0.000185	CcSEcCtD
Delavirdine—Fatigue—Betamethasone—psoriasis	5.16e-05	0.000185	CcSEcCtD
Delavirdine—Fatigue—Dexamethasone—psoriasis	5.16e-05	0.000185	CcSEcCtD
Delavirdine—Shock—Prednisone—psoriasis	5.13e-05	0.000184	CcSEcCtD
Delavirdine—Pain—Dexamethasone—psoriasis	5.12e-05	0.000183	CcSEcCtD
Delavirdine—Pain—Betamethasone—psoriasis	5.12e-05	0.000183	CcSEcCtD
Delavirdine—Tachycardia—Prednisone—psoriasis	5.09e-05	0.000182	CcSEcCtD
Delavirdine—Dizziness—Mycophenolate mofetil—psoriasis	5.09e-05	0.000182	CcSEcCtD
Delavirdine—Skin disorder—Prednisone—psoriasis	5.07e-05	0.000181	CcSEcCtD
Delavirdine—Hyperhidrosis—Prednisone—psoriasis	5.04e-05	0.00018	CcSEcCtD
Delavirdine—Vision blurred—Methotrexate—psoriasis	5.03e-05	0.00018	CcSEcCtD
Delavirdine—Asthenia—Hydrocortisone—psoriasis	5.03e-05	0.00018	CcSEcCtD
Delavirdine—Vomiting—Cyclosporine—psoriasis	5.01e-05	0.00018	CcSEcCtD
Delavirdine—Rash—Cyclosporine—psoriasis	4.97e-05	0.000178	CcSEcCtD
Delavirdine—Anorexia—Prednisone—psoriasis	4.97e-05	0.000178	CcSEcCtD
Delavirdine—Dermatitis—Cyclosporine—psoriasis	4.97e-05	0.000178	CcSEcCtD
Delavirdine—Pruritus—Hydrocortisone—psoriasis	4.96e-05	0.000178	CcSEcCtD
Delavirdine—Ill-defined disorder—Methotrexate—psoriasis	4.95e-05	0.000177	CcSEcCtD
Delavirdine—Headache—Cyclosporine—psoriasis	4.94e-05	0.000177	CcSEcCtD
Delavirdine—Anaemia—Methotrexate—psoriasis	4.94e-05	0.000177	CcSEcCtD
Delavirdine—Feeling abnormal—Dexamethasone—psoriasis	4.93e-05	0.000177	CcSEcCtD
Delavirdine—Feeling abnormal—Betamethasone—psoriasis	4.93e-05	0.000177	CcSEcCtD
Delavirdine—Gastrointestinal pain—Dexamethasone—psoriasis	4.9e-05	0.000175	CcSEcCtD
Delavirdine—Gastrointestinal pain—Betamethasone—psoriasis	4.9e-05	0.000175	CcSEcCtD
Delavirdine—Vomiting—Mycophenolate mofetil—psoriasis	4.89e-05	0.000175	CcSEcCtD
Delavirdine—Hypersensitivity—Triamcinolone—psoriasis	4.86e-05	0.000174	CcSEcCtD
Delavirdine—Rash—Mycophenolate mofetil—psoriasis	4.85e-05	0.000174	CcSEcCtD
Delavirdine—Dermatitis—Mycophenolate mofetil—psoriasis	4.85e-05	0.000173	CcSEcCtD
Delavirdine—Headache—Mycophenolate mofetil—psoriasis	4.82e-05	0.000173	CcSEcCtD
Delavirdine—Malaise—Methotrexate—psoriasis	4.82e-05	0.000172	CcSEcCtD
Delavirdine—Vertigo—Methotrexate—psoriasis	4.8e-05	0.000172	CcSEcCtD
Delavirdine—Diarrhoea—Hydrocortisone—psoriasis	4.8e-05	0.000172	CcSEcCtD
Delavirdine—Leukopenia—Methotrexate—psoriasis	4.78e-05	0.000171	CcSEcCtD
Delavirdine—Urticaria—Dexamethasone—psoriasis	4.76e-05	0.00017	CcSEcCtD
Delavirdine—Urticaria—Betamethasone—psoriasis	4.76e-05	0.00017	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Prednisone—psoriasis	4.75e-05	0.00017	CcSEcCtD
Delavirdine—Dizziness—Prednisolone—psoriasis	4.75e-05	0.00017	CcSEcCtD
Delavirdine—Asthenia—Triamcinolone—psoriasis	4.74e-05	0.00017	CcSEcCtD
Delavirdine—Abdominal pain—Betamethasone—psoriasis	4.73e-05	0.000169	CcSEcCtD
Delavirdine—Abdominal pain—Dexamethasone—psoriasis	4.73e-05	0.000169	CcSEcCtD
Delavirdine—Body temperature increased—Dexamethasone—psoriasis	4.73e-05	0.000169	CcSEcCtD
Delavirdine—Body temperature increased—Betamethasone—psoriasis	4.73e-05	0.000169	CcSEcCtD
Delavirdine—Insomnia—Prednisone—psoriasis	4.72e-05	0.000169	CcSEcCtD
Delavirdine—Nausea—Cyclosporine—psoriasis	4.68e-05	0.000168	CcSEcCtD
Delavirdine—Paraesthesia—Prednisone—psoriasis	4.68e-05	0.000168	CcSEcCtD
Delavirdine—Pruritus—Triamcinolone—psoriasis	4.67e-05	0.000167	CcSEcCtD
Delavirdine—Cough—Methotrexate—psoriasis	4.66e-05	0.000167	CcSEcCtD
Delavirdine—Dizziness—Hydrocortisone—psoriasis	4.63e-05	0.000166	CcSEcCtD
Delavirdine—Dyspepsia—Prednisone—psoriasis	4.59e-05	0.000164	CcSEcCtD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.58e-05	0.00204	CbGpPWpGaD
Delavirdine—Nausea—Mycophenolate mofetil—psoriasis	4.57e-05	0.000164	CcSEcCtD
Delavirdine—Chest pain—Methotrexate—psoriasis	4.55e-05	0.000163	CcSEcCtD
Delavirdine—Myalgia—Methotrexate—psoriasis	4.55e-05	0.000163	CcSEcCtD
Delavirdine—Arthralgia—Methotrexate—psoriasis	4.55e-05	0.000163	CcSEcCtD
Delavirdine—Decreased appetite—Prednisone—psoriasis	4.53e-05	0.000162	CcSEcCtD
Delavirdine—Rash—Prednisolone—psoriasis	4.52e-05	0.000162	CcSEcCtD
Delavirdine—Dermatitis—Prednisolone—psoriasis	4.52e-05	0.000162	CcSEcCtD
Delavirdine—Fatigue—Prednisone—psoriasis	4.5e-05	0.000161	CcSEcCtD
Delavirdine—Headache—Prednisolone—psoriasis	4.5e-05	0.000161	CcSEcCtD
Delavirdine—Discomfort—Methotrexate—psoriasis	4.49e-05	0.000161	CcSEcCtD
Delavirdine—Constipation—Prednisone—psoriasis	4.46e-05	0.00016	CcSEcCtD
Delavirdine—Vomiting—Hydrocortisone—psoriasis	4.46e-05	0.00016	CcSEcCtD
Delavirdine—Rash—Hydrocortisone—psoriasis	4.42e-05	0.000158	CcSEcCtD
Delavirdine—CYP3A7—Metabolism—NDUFA5—psoriasis	4.42e-05	0.00197	CbGpPWpGaD
Delavirdine—Dermatitis—Hydrocortisone—psoriasis	4.42e-05	0.000158	CcSEcCtD
Delavirdine—Confusional state—Methotrexate—psoriasis	4.39e-05	0.000157	CcSEcCtD
Delavirdine—Headache—Hydrocortisone—psoriasis	4.39e-05	0.000157	CcSEcCtD
Delavirdine—Dizziness—Triamcinolone—psoriasis	4.36e-05	0.000156	CcSEcCtD
Delavirdine—Infection—Methotrexate—psoriasis	4.33e-05	0.000155	CcSEcCtD
Delavirdine—Feeling abnormal—Prednisone—psoriasis	4.3e-05	0.000154	CcSEcCtD
Delavirdine—Asthenia—Dexamethasone—psoriasis	4.3e-05	0.000154	CcSEcCtD
Delavirdine—Asthenia—Betamethasone—psoriasis	4.3e-05	0.000154	CcSEcCtD
Delavirdine—Thrombocytopenia—Methotrexate—psoriasis	4.27e-05	0.000153	CcSEcCtD
Delavirdine—Gastrointestinal pain—Prednisone—psoriasis	4.26e-05	0.000153	CcSEcCtD
Delavirdine—Nausea—Prednisolone—psoriasis	4.26e-05	0.000153	CcSEcCtD
Delavirdine—Pruritus—Dexamethasone—psoriasis	4.24e-05	0.000152	CcSEcCtD
Delavirdine—Pruritus—Betamethasone—psoriasis	4.24e-05	0.000152	CcSEcCtD
Delavirdine—Skin disorder—Methotrexate—psoriasis	4.23e-05	0.000152	CcSEcCtD
Delavirdine—Hyperhidrosis—Methotrexate—psoriasis	4.21e-05	0.000151	CcSEcCtD
Delavirdine—Vomiting—Triamcinolone—psoriasis	4.2e-05	0.00015	CcSEcCtD
Delavirdine—Nausea—Hydrocortisone—psoriasis	4.16e-05	0.000149	CcSEcCtD
Delavirdine—Rash—Triamcinolone—psoriasis	4.16e-05	0.000149	CcSEcCtD
Delavirdine—Dermatitis—Triamcinolone—psoriasis	4.16e-05	0.000149	CcSEcCtD
Delavirdine—Anorexia—Methotrexate—psoriasis	4.15e-05	0.000149	CcSEcCtD
Delavirdine—Urticaria—Prednisone—psoriasis	4.14e-05	0.000148	CcSEcCtD
Delavirdine—Headache—Triamcinolone—psoriasis	4.13e-05	0.000148	CcSEcCtD
Delavirdine—Abdominal pain—Prednisone—psoriasis	4.12e-05	0.000148	CcSEcCtD
Delavirdine—Body temperature increased—Prednisone—psoriasis	4.12e-05	0.000148	CcSEcCtD
Delavirdine—Diarrhoea—Betamethasone—psoriasis	4.1e-05	0.000147	CcSEcCtD
Delavirdine—Diarrhoea—Dexamethasone—psoriasis	4.1e-05	0.000147	CcSEcCtD
Delavirdine—Hypotension—Methotrexate—psoriasis	4.07e-05	0.000146	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Methotrexate—psoriasis	3.97e-05	0.000142	CcSEcCtD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.96e-05	0.00176	CbGpPWpGaD
Delavirdine—Dizziness—Betamethasone—psoriasis	3.96e-05	0.000142	CcSEcCtD
Delavirdine—Dizziness—Dexamethasone—psoriasis	3.96e-05	0.000142	CcSEcCtD
Delavirdine—Insomnia—Methotrexate—psoriasis	3.94e-05	0.000141	CcSEcCtD
Delavirdine—Nausea—Triamcinolone—psoriasis	3.92e-05	0.00014	CcSEcCtD
Delavirdine—Paraesthesia—Methotrexate—psoriasis	3.91e-05	0.00014	CcSEcCtD
Delavirdine—Dyspnoea—Methotrexate—psoriasis	3.89e-05	0.000139	CcSEcCtD
Delavirdine—Somnolence—Methotrexate—psoriasis	3.87e-05	0.000139	CcSEcCtD
Delavirdine—Hypersensitivity—Prednisone—psoriasis	3.84e-05	0.000138	CcSEcCtD
Delavirdine—Dyspepsia—Methotrexate—psoriasis	3.84e-05	0.000137	CcSEcCtD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.81e-05	0.0017	CbGpPWpGaD
Delavirdine—Vomiting—Dexamethasone—psoriasis	3.81e-05	0.000136	CcSEcCtD
Delavirdine—Vomiting—Betamethasone—psoriasis	3.81e-05	0.000136	CcSEcCtD
Delavirdine—Decreased appetite—Methotrexate—psoriasis	3.79e-05	0.000136	CcSEcCtD
Delavirdine—Rash—Dexamethasone—psoriasis	3.78e-05	0.000135	CcSEcCtD
Delavirdine—Rash—Betamethasone—psoriasis	3.78e-05	0.000135	CcSEcCtD
Delavirdine—Dermatitis—Dexamethasone—psoriasis	3.77e-05	0.000135	CcSEcCtD
Delavirdine—Dermatitis—Betamethasone—psoriasis	3.77e-05	0.000135	CcSEcCtD
Delavirdine—Gastrointestinal disorder—Methotrexate—psoriasis	3.76e-05	0.000135	CcSEcCtD
Delavirdine—Fatigue—Methotrexate—psoriasis	3.76e-05	0.000135	CcSEcCtD
Delavirdine—CYP3A7—Metabolism—CYP2S1—psoriasis	3.76e-05	0.00167	CbGpPWpGaD
Delavirdine—Headache—Betamethasone—psoriasis	3.75e-05	0.000134	CcSEcCtD
Delavirdine—Headache—Dexamethasone—psoriasis	3.75e-05	0.000134	CcSEcCtD
Delavirdine—Asthenia—Prednisone—psoriasis	3.74e-05	0.000134	CcSEcCtD
Delavirdine—Pain—Methotrexate—psoriasis	3.73e-05	0.000133	CcSEcCtD
Delavirdine—Pruritus—Prednisone—psoriasis	3.69e-05	0.000132	CcSEcCtD
Delavirdine—Feeling abnormal—Methotrexate—psoriasis	3.59e-05	0.000129	CcSEcCtD
Delavirdine—Diarrhoea—Prednisone—psoriasis	3.57e-05	0.000128	CcSEcCtD
Delavirdine—Gastrointestinal pain—Methotrexate—psoriasis	3.56e-05	0.000128	CcSEcCtD
Delavirdine—Nausea—Betamethasone—psoriasis	3.56e-05	0.000127	CcSEcCtD
Delavirdine—Nausea—Dexamethasone—psoriasis	3.56e-05	0.000127	CcSEcCtD
Delavirdine—Urticaria—Methotrexate—psoriasis	3.46e-05	0.000124	CcSEcCtD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.46e-05	0.00154	CbGpPWpGaD
Delavirdine—Dizziness—Prednisone—psoriasis	3.45e-05	0.000123	CcSEcCtD
Delavirdine—Abdominal pain—Methotrexate—psoriasis	3.45e-05	0.000123	CcSEcCtD
Delavirdine—Body temperature increased—Methotrexate—psoriasis	3.45e-05	0.000123	CcSEcCtD
Delavirdine—Vomiting—Prednisone—psoriasis	3.32e-05	0.000119	CcSEcCtD
Delavirdine—Rash—Prednisone—psoriasis	3.29e-05	0.000118	CcSEcCtD
Delavirdine—Dermatitis—Prednisone—psoriasis	3.29e-05	0.000118	CcSEcCtD
Delavirdine—Headache—Prednisone—psoriasis	3.27e-05	0.000117	CcSEcCtD
Delavirdine—Hypersensitivity—Methotrexate—psoriasis	3.21e-05	0.000115	CcSEcCtD
Delavirdine—CYP3A5—Metabolism—NDUFA5—psoriasis	3.19e-05	0.00142	CbGpPWpGaD
Delavirdine—Asthenia—Methotrexate—psoriasis	3.13e-05	0.000112	CcSEcCtD
Delavirdine—Nausea—Prednisone—psoriasis	3.1e-05	0.000111	CcSEcCtD
Delavirdine—Pruritus—Methotrexate—psoriasis	3.08e-05	0.00011	CcSEcCtD
Delavirdine—Diarrhoea—Methotrexate—psoriasis	2.98e-05	0.000107	CcSEcCtD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.97e-05	0.00132	CbGpPWpGaD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.97e-05	0.00132	CbGpPWpGaD
Delavirdine—Dizziness—Methotrexate—psoriasis	2.88e-05	0.000103	CcSEcCtD
Delavirdine—Vomiting—Methotrexate—psoriasis	2.77e-05	9.92e-05	CcSEcCtD
Delavirdine—CYP2C8—Metabolism—NDUFA5—psoriasis	2.77e-05	0.00123	CbGpPWpGaD
Delavirdine—Rash—Methotrexate—psoriasis	2.75e-05	9.84e-05	CcSEcCtD
Delavirdine—Dermatitis—Methotrexate—psoriasis	2.75e-05	9.83e-05	CcSEcCtD
Delavirdine—Headache—Methotrexate—psoriasis	2.73e-05	9.77e-05	CcSEcCtD
Delavirdine—CYP3A5—Metabolism—CYP2S1—psoriasis	2.72e-05	0.00121	CbGpPWpGaD
Delavirdine—Nausea—Methotrexate—psoriasis	2.59e-05	9.27e-05	CcSEcCtD
Delavirdine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.58e-05	0.00115	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.47e-05	0.0011	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.35e-05	0.00105	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.3e-05	0.00102	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.27e-05	0.00101	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.25e-05	0.001	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.1e-05	0.000934	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.1e-05	0.000934	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.93e-05	0.000859	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.92e-05	0.000856	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.91e-05	0.000852	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—CARM1—psoriasis	1.83e-05	0.000817	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.79e-05	0.000798	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.64e-05	0.000728	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.48e-05	0.000661	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—CARM1—psoriasis	1.33e-05	0.00059	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.26e-05	0.000562	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	0.000549	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—CARM1—psoriasis	1.15e-05	0.000511	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—CAT—psoriasis	1.13e-05	0.000502	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.1e-05	0.00049	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	0.000478	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—CARM1—psoriasis	1.03e-05	0.000456	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1e-05	0.000447	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.58e-06	0.000427	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—CARM1—psoriasis	9.43e-06	0.00042	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—CARM1—psoriasis	9.35e-06	0.000416	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—APOE—psoriasis	8.77e-06	0.00039	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.74e-06	0.000389	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.57e-06	0.000382	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—CAT—psoriasis	8.16e-06	0.000363	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—CARM1—psoriasis	7.99e-06	0.000356	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—PPARG—psoriasis	7.64e-06	0.00034	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.47e-06	0.000332	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—CAT—psoriasis	7.06e-06	0.000314	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—APOE—psoriasis	6.34e-06	0.000282	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—CAT—psoriasis	6.31e-06	0.000281	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—CARM1—psoriasis	6.16e-06	0.000274	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—CAT—psoriasis	5.8e-06	0.000258	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—CAT—psoriasis	5.75e-06	0.000256	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—PPARG—psoriasis	5.52e-06	0.000246	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—APOE—psoriasis	5.49e-06	0.000244	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—CAT—psoriasis	4.91e-06	0.000219	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—APOE—psoriasis	4.9e-06	0.000218	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—PPARG—psoriasis	4.78e-06	0.000213	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—APOE—psoriasis	4.51e-06	0.000201	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—APOE—psoriasis	4.47e-06	0.000199	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—PPARG—psoriasis	4.27e-06	0.00019	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—PPARG—psoriasis	3.92e-06	0.000175	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—PPARG—psoriasis	3.89e-06	0.000173	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—APOE—psoriasis	3.82e-06	0.00017	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—CAT—psoriasis	3.79e-06	0.000169	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—PPARG—psoriasis	3.32e-06	0.000148	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—APOE—psoriasis	2.95e-06	0.000131	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—PPARG—psoriasis	2.57e-06	0.000114	CbGpPWpGaD
